跳至主要内容
临床试验/NCT02245542
NCT02245542已完成不适用

The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Boehringer Ingelheim0 个研究点目标入组 5,775 人开始时间: 2005年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
5,775
主要终点
Change from Baseline in Nocturia quality of life by means of a patient questionnaire

研究概览

简要总结

Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
Male
接受健康志愿者

入选标准

  • Indication for treatment with ALNA®OCAS® according to the prescribing information for a minimum period of three months

排除标准

  • Patients fulfilling one of the general or specific contraindications listed in the ALNA®OCAS® Summary of Product Characteristics (SPC), particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency could not be included in the Post Marketing Study (PMS) study

研究组 & 干预措施

BPH patients

干预措施: ALNA®OCAS® (Drug)

结局指标

主要结局

Change from Baseline in Nocturia quality of life by means of a patient questionnaire

时间窗: Baseline, after 3 months

Change from Baseline in International Prostatic Symptom Score (IPSS) by means of a patient questionnaire

时间窗: Baseline, after 3 months

次要结局

  • Change from Baseline in residual urine volume(Baseline, after 3 months)
  • Number of patients with adverse events(up to 3 months)
  • Assessment of tolerability by investigator on 4-point scale(after 3 months)
  • Change from Baseline in Maximum urinary flow rate (Qmax)(Baseline, after 3 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

The Impact of Alna® Ocas® on Nocturia in Patients... | 临床试验